ET collaborates with
Terumo Blood Cell Technologies

Upcoming development and commercialization of a novel therapeutic apheresis treatment for acute kidney injury (AKI)

Learn More


ETI Awarded $1.7 million by NIH

For XGAL-3s Apheresis Large Animal Safety Study

Learn More


mission + target
Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis. Our mission is to change the course of life-threatening diseases to improve survival and prevent long-term disease and disability.

The Problem

Acute Kidney Injury (AKI) is a common and potentially life-threatening condition. AKI affects over 4 million people in the United States with an annual cost of up to $24.0 billion. Despite efforts to develop new therapeutic modalities, current therapeutic options remain very limited.

Learn More

The Solution

Eliaz Therapeutics is developing a novel medical device to selectively remove galectin-3 from the bloodstream.

(Gal-3) is an important mediator and known key driver of organ inflammation and fibrosis in numerous acute and chronic progressive conditions. In critically ill patients, the development of AKI and sepsis is associated with increased plasma Gal-3 levels. When Gal-3 is blocked in animal models, AKI rates significantly decrease and survival increases.

Find out how we have developed the technology to target and remove Gal-3 directly from the bloodstream.

Learn More
What is Galectin-3?

The Hidden Cause of Chronic Disease

Galectin-3 (Gal-3) is protein that our bodies produce increasingly overtime, due to stress, injury, and aging. This protein has been clinically proven in 3,000 studies to cause a wide range of health issues. Many of the chronic illnesses we, and our loved ones face every day can be traced back to the damages caused by this one protein.

What are some of the health effects caused by Galectin-3?

  • Kidney Disease
  • Sepsis
  • Inflammation
  • Heart Disease
  • Fibrosis
  • Cancer
How do we remove Galectin-3 from our bodies?

XGal-3 Column

Enhancing Apheresis technology

The single-use XGal-3 apheresis column selectively removes Galectin-3 from the body. XGal-3 contains a proprietary, highly effective capturing molecule and is built in a format that hospitals already know how to use.

Nothing goes into the patient's body.
100% disposable with effective removal.
Easy Adoption
Fits into existing apheresis systems.

How it works

Join us in fighting life-threatening diseases.
Learn more about our current investment programs.